Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Nucleus matrix Nucleus speckle. Chromosome. Note=Colocalizes with the Ten-1 ICD form of TENM1 in foci associated with the nuclear matrix (By similarity). Nuclear, in a punctate pattern. Associated with euchromatic regions of the chromosomes, with pericentromeric regions on chromosome 1 and with telomeric regions from several chromosomes. |
Domain |
PF01429 Methyl-CpG binding domain PF02008 CXXC zinc finger domain |
Function |
Transcriptional repressor that binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binding is abolished by the presence of 7-mG that is produced by DNA damage by methylmethanesulfonate (MMS). Acts as transcriptional repressor and plays a role in gene silencing by recruiting AFT7IP, which in turn recruits factors such as the histone methyltransferase SETDB1. Probably forms a complex with SETDB1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also repress transcription from unmethylated promoters. |
Biological Process |
GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0006342 chromatin silencing GO:0006346 methylation-dependent chromatin silencing GO:0007507 heart development GO:0007568 aging GO:0009991 response to extracellular stimulus GO:0010001 glial cell differentiation GO:0010721 negative regulation of cell development GO:0014013 regulation of gliogenesis GO:0014014 negative regulation of gliogenesis GO:0016458 gene silencing GO:0031667 response to nutrient levels GO:0032259 methylation GO:0032355 response to estradiol GO:0040029 regulation of gene expression, epigenetic GO:0042063 gliogenesis GO:0042220 response to cocaine GO:0043279 response to alkaloid GO:0043414 macromolecule methylation GO:0044030 regulation of DNA methylation GO:0044728 DNA methylation or demethylation GO:0045685 regulation of glial cell differentiation GO:0045686 negative regulation of glial cell differentiation GO:0045814 negative regulation of gene expression, epigenetic GO:0048708 astrocyte differentiation GO:0048710 regulation of astrocyte differentiation GO:0048712 negative regulation of astrocyte differentiation GO:0050768 negative regulation of neurogenesis GO:0051052 regulation of DNA metabolic process GO:0051961 negative regulation of nervous system development |
Molecular Function |
GO:0003682 chromatin binding GO:0008327 methyl-CpG binding GO:0010385 double-stranded methylated DNA binding |
Cellular Component |
GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0016363 nuclear matrix GO:0016604 nuclear body GO:0016607 nuclear speck GO:0034399 nuclear periphery GO:0044454 nuclear chromosome part |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MBD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MBD1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MBD1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MBD1 in various data sets.
|
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MBD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MBD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MBD1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MBD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MBD1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MBD1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MBD1 |
Name | methyl-CpG binding domain protein 1 |
Aliases | CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ...... |
Chromosomal Location | 18q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MBD1 collected from DrugBank database. |
There is no record. |